Clearance of hepatitis C virus after newly acquired infection in injection drug users

Marianne Jauncey, Joanne M. Micallef, Stuart Gilmour, Janaki Amin, Peter A. White, William Rawlinson, John M. Kaldor, Ingrid van Beek, Gregory J. Dore*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

67 Citations (Scopus)

Abstract

A retrospective cohort of injection drug users with newly acquired hepatitis C virus (HCV) infection was established to examine viral clearance. Newly acquired HCV infection was defined by anti-HCV antibody seroconversion within a 2-year interval. Stored serum samples were tested for HCV RNA, with viral clearance defined as ≥2 consecutive negative HCV RNA test results after infection. Ninety-nine cases of HCV infection were identified; 57 had ≥2 HCV RNA test results after infection. Viral clearance occurred in 24 (42%) cases, with Kaplan-Meier estimated probabilities of 23%, 38%, and 40% at 6, 12, and 24 months, respectively.

Original languageEnglish
Pages (from-to)1270-1274
Number of pages5
JournalJournal of Infectious Diseases
Volume190
Issue number7
DOIs
Publication statusPublished - 1 Oct 2004
Externally publishedYes

Fingerprint

Dive into the research topics of 'Clearance of hepatitis C virus after newly acquired infection in injection drug users'. Together they form a unique fingerprint.

Cite this